OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+13.93%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$494M
AUM Growth
+$494M
(+10%)
Cap. Flow
+$17.1M
Cap. Flow
% of AUM
3.47%
Top 10 Holdings %
Top 10 Hldgs %
73.47%
Holding
50
New
5
Increased
15
Reduced
12
Closed
9
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$8.55M |
| 2 |
VIGL
Vigil Neuroscience
VIGL
|
$7.95M |
| 3 |
Codexis
CDXS
|
$7.56M |
| 4 |
Larimar Therapeutics
LRMR
|
$6.35M |
| 5 |
Disc Medicine
IRON
|
$5.37M |
Top Sells
| 1 |
Ginkgo Bioworks
DNA
|
$7.82M |
| 2 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$4.82M |
| 3 |
AnaptysBio
ANAB
|
$4.66M |
| 4 |
SLRN
ACELYRIN
SLRN
|
$3.99M |
| 5 |
Protara Therapeutics
TARA
|
$2.65M |
Sector Composition
| 1 | Healthcare | 97.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Harrow
HROW
$1.44B
| $119M | 24.13% | 3,905,000 -50,000 | -1% | -$1.53M |
|
2
Eton Pharmaceutcials
ETON
$464M
| $40.8M | 8.25% | 2,860,000 +7,930 | +0.3% | +$113K |
|
3
Immunome
IMNM
$828M
| $32.8M | 6.64% | 3,529,581 -20,419 | -0.6% | -$190K |
|
|
SNWV
4
SANUWAVE Health, Inc. Common Stock
SNWV
$357M
| $32.2M | 6.52% | 980,000 +7,998 | +0.8% | +$263K |
|
5
Liquidia Corp
LQDA
$2.38B
| $30.8M | 6.24% | 2,475,000 +215,000 | +10% | +$2.68M |
|
|
6
Codexis
CDXS
$246M
| $30.7M | 6.22% | 12,600,000 +3,100,000 | +33% | +$7.56M |
|
7
Rhythm Pharmaceuticals
RYTM
$6.85B
| $30M | 6.07% | 475,000 -15,000 | -3% | -$948K |
|
8
TG Therapeutics
TGTX
$4.65B
| $19.3M | 3.9% | 535,000 | – | – |
|
9
Ocular Therapeutix
OCUL
$2.12B
| $14.8M | 3% | 1,595,000 | – | – |
|
10
Arvinas
ARVN
$568M
| $12.4M | 2.5% | 1,680,000 -295,000 | -15% | -$2.17M |
|
|
11
Larimar Therapeutics
LRMR
$310M
| $11.9M | 2.4% | 4,110,000 +2,195,923 | +115% | +$6.35M |
|
|
12
Disc Medicine
IRON
$2.07B
| $9.87M | 2% | 186,418 +101,418 | +119% | +$5.37M |
|
|
13
Sarepta Therapeutics
SRPT
$1.78B
| $8.55M | 1.73% | +500,000 | New | +$8.55M |
|
|
VIGL
14
DELISTED
Vigil Neuroscience
VIGL
| $7.95M | 1.61% | +1,000,000 | New | +$7.95M |
|
15
CG Oncology
CGON
$2.04B
| $6.92M | 1.4% | 266,000 +102,012 | +62% | +$2.65M |
|
16
Xoma
XOMA
$392M
| $6.43M | 1.3% | 255,087 +2,044 | +0.8% | +$51.5K |
|
17
Edgewise Therapeutics
EWTX
$1.51B
| $6.42M | 1.3% | 490,000 +95,000 | +24% | +$1.25M |
|
18
Stoke Therapeutics
STOK
$1.08B
| $6.38M | 1.29% | 562,120 +262,120 | +87% | +$2.98M |
|
19
Anika Therapeutics
ANIK
$135M
| $6.23M | 1.26% | 588,797 +193,797 | +49% | +$2.05M |
|
20
Protagonist Therapeutics
PTGX
$3.67B
| $5.8M | 1.17% | 105,000 | – | – |
|
|
21
Ginkgo Bioworks
DNA
$750M
| $5.63M | 1.14% | 500,000 -695,000 | -58% | -$7.82M |
|
22
Gossamer Bio
GOSS
$562M
| $4.36M | 0.88% | 3,545,000 -742,415 | -17% | -$913K |
|
23
Rezolute
RZLT
$619M
| $4.03M | 0.82% | 903,442 +438,442 | +94% | +$1.96M |
|
24
Revolution Medicines
RVMD
$7.1B
| $3.86M | 0.78% | +105,000 | New | +$3.86M |
|
25
ESSA Pharma
EPIX
$11.4M
| $3.76M | 0.76% | 2,209,998 | – | – |
|